Issue link: http://osercommunicationsgroup.uberflip.com/i/265897
C h a i n D r u g s t o r e D a i l y 2 3 M o n d a y, A u g u s t 1 2 , 2 0 1 3 CAMBER OFFERS NEW GENERIC PRODUCTS Camber is a rapidly growing sales and marketing company with a mission to pro- vide exceptional value in the expanding generics marketplace. Camber's parent company, Hetero Drugs of Hyderabad, India, is a leader in the production of APIs. Hetero Drugs employs more than 12,000 workers, including more than 350 scien- tists, at its seven facilities. Hetero has a global presence in more than 100 coun- tries, including an associate company in the United States: generic manufacturer, InvaGen Pharmaceuticals, Inc., of Hauppauge, N.Y. Hetero Drugs' state-of-the-art facili- ties and features include four FDA- approved sites for API, three FDA- approved sites for finished goods, more than 100 DMFs filed, and facilities and joint ventures in India, the United States, Canada, Mexico, South America, Europe, the Middle East, Africa, Asia and Australia. Camber's current line and future products include a wide range of therapeutic categories, including anti- retroviral, antiulcerant, antineoplastic, cardiovascular, antibacterial, antidepres- sant, antidiabetics and more. With new product releases that include Escitalopram Tablets and Solution, Indomethacin ER, Irbesartan, Levocetirizine, and Zonisamide. Camber will remain one of the fastest growing generic companies in the United States for years to come. Located in Piscataway, N.J., Camber Pharmaceuticals is a fully inte- grated international pharmaceutical com- pany that maintains quality and integrity in all its products from API manufactur- ing to finished dosage. For more information about Camber Pharmaceuticals, visit booth 4011 at the NACDS Total Store Expo, visit www.cam- berpharma.com or call 732-529-0430. DELIVERING VALUE IN THE SUPPLY CHAIN "Once the C-suite recognizes that a mature supply chain is truly a source of important competitive advantage, it will be easier to persuade executives to make the invest- ments needed to bring supply chains up to the next level." —PricewaterhouseCoopers (PwC) Global Supply Chain Survey 2013 ( w w w . p w c . c o m / G l o b a l S u p p l y ChainSurvey2013). In 2013, information is king. Technology has moved the supply chain forward in a short amount of time. There are now vast repositories of data that can give drill down visibility at major points in the supply chain to pinpoint when damages occur and where profitability can be improved. For the C-suite, prof- itability and insight are key to under- standing that there is value in a strong supply chain partner who can provide this data. In the same way that corpora- tions hire outside legal counsel or payroll providers – since these are not their core competencies – the same is true of hiring an outside resource to gather the data and supply the analytics to improve the sup- ply chain. As a supply chain consultant partner, Inmar entered into a strategic relation- ship with a national retailer and a health- care manufacturer to provide information regarding the root causes of unsaleables and to develop an action plan to address this challenge and ultimately reduce unsaleables. Concurrently, the manufac- turer refocused organizational resources on unsaleables, creating a dedicated cross-functional team charged with breaking down operational silos and collaborating fully to opti- mize applicable, internal process- es in the value chain. This project involved taking a look at categories of products on the retail shelves to collect information at the con- sumer unit level related to expiration. Inmar gathered data on products in the pain, digestive health, cough/ cold/allergy/sinus and stretch categories at 40 retailer locations across the country. The Inmar team looked at all the manu- facturer's products in stock within each category, recorded the expiration data and made observation of the current rotation. The manufacturer collaborated with their trading partner to understand un- forecasted inventory builds and mitigate downstream unsaleables risk at retail. Inventory needs were validated by SKU and DC. In many instances, order quanti- ties were reduced by almost 40 percent. The manufacturer decreased unsaleables by 29 percent from the previous year at the specific retailer they partnered with for the study and overall they decreased unsaleables by $5 million over the previ- ous year. With new technology, data collec- tion in-store at the retail shelf is avail- able with real-time information that can be used to develop bottom line enhanc- ing processes. The ability to collect that data and gain insight from it is the requirement of competitive supply chains in 2013. From promotion compli- ance, point of sale audits to shelf quali- ty studies, the right technology can make a trip to a single retailer become a full data collection experience. For more information, contact Inmar at solutions@inmar.com or visit www.inmar.com. Visit booth 5225 for a demonstration. THE NEW ACTAVIS: WORLD-CLASS CAPABILITIES, PRODUCT PORTFOLIOS, CUSTOMER SERVICE In late 2012, Watson Pharmaceuticals completed the acquisition of Actavis Group, resulting in the creation of the world's third largest generics manufac- turer. Following the acquisition, Watson changed its name to Actavis (NYSE: ACT) and launched a dynamic new logo and mission for the combined company. Today, the new Actavis serves more than 5 billion customers in more than 62 countries with an expanded product port- folio, industry-leading customer service, and world class manufacturing and sup- ply chain capabilities. In the U.S., Actavis holds a leading market position with an extensive portfo- lio of solid dosage, oral controlled and sustained release, transdermal, injectable, gel, semi-solid and oral transmucosal products in key therapeutic categories. Actavis product in the U.S. is currently distributed under the Watson and Actavis labels as the company continues to work through a rebranding initiative that will ultimately result in the conver- sion of all products to the new Actavis brand. To ensure continued value for its customers and for patients, Actavis has developed one of the strongest U.S. generics pipelines, with more than 185 ANDAs on file, near- ly 50 of which are first-to-file applica- tions. Products in the generic pipeline represent the company's focused R&D strategy on the development of generics that are difficult to formulate or manu- facture or will complement or broaden existing product lines. Actavis leadership in the U.S. is sup- ported by customer service and a supply chain that is among the best in the indus- try. Recognized with several Partner and Supplier of the Year awards from key customers, the com- pany is frequently acknowl- edged for its commitment to service, fast and smart delivery of product, and consistent ability to deliver on its promises to customers. Beyond its commercial commit- ments, the new Actavis is enhancing its commitment to social and environmental responsibility, serving as a national cor- porate sponsor for March of Dimes, and serving as a partner in The Medicine Abuse Project and several other local and national not-for-profit organizations. Learn more about the new Actavis at NACDS Booth 2121 or visit www.Actavis.com. KNAPP INTRODUCES KISOFT VISION TECHNOLOGY FOR TABLET/CAPSULE VERIFICATION KNAPP Logistics Automation, Inc. is a global leader in pharmacy and prescrip- tion automation and continues its impres- sive history of innovation with the intro- duction of KiSoft Vision. KNAPP devel- oped KiSoft Vision based on augmented reality principles over four years ago and has integrated this technology into many material-handling solutions. This latest example of innovation ensures patient safety through easy visual verification of the correct tablet/capsule for the proper prescription. The usability of this tech- nology is for vial/bottle and blister/med- ication cards. As the National Drug Code (NDC) database continues to grow and expand, it stores the complete NDC profile in the client's database, including all charac- teristics such as image, color, size, shape, etc. This allows Vision technolo- gy recognition software to utilize high resolution digital scanners/cameras to accurately and quickly verify proper sequences and orientation on items such as blister cards. Vision recognition soft- ware also authenticates unique attributes of tablets/capsule such as shape (length, width, contour), specific surface letter and number imprints, color and color deviations, broken/chipped tablets, and empty capsules or missing items. Any anomalies detected are reported and the questionable item is sent for secondary verification by a pharmacist. In addition to tablet/capsule verifi- cation, Vision technology can be used to confirm patient label statistics – bar- code/prescription information, patient details and product ID – and images of patient and blister/vial filled tablets are captured and stored for future reference if needed. Real time updates and/or reports are generated for any combina- tion of flags or alerts loaded into the software database. KNAPP Logistics Automation Inc., a member of the KNAPP group, is head- quartered in Kennesaw, Ga. KNAPP has been a leader in improving prescription accuracy and safety since introduction of its original automated tablet dispenser in 1999. On-going development of cutting- edge features help pharmacies improve their throughput and efficiency by designing and implementing counting and dispensing products that ultimately lead to enhanced levels of quality, safety, and speed, both for the patients and for the pharmacy. For more information, contact KNAPP at 678-388-2880, email sales.us @knapp.com, stop by booth 517 at the 2013 NACDS Total Store Expo or visit www.KNAPP.com.